JP2017514801A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514801A5
JP2017514801A5 JP2016561311A JP2016561311A JP2017514801A5 JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5 JP 2016561311 A JP2016561311 A JP 2016561311A JP 2016561311 A JP2016561311 A JP 2016561311A JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5
Authority
JP
Japan
Prior art keywords
xaa
chem
glu
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016561311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514801A (ja
JP6768515B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/057442 external-priority patent/WO2015155151A1/en
Publication of JP2017514801A publication Critical patent/JP2017514801A/ja
Publication of JP2017514801A5 publication Critical patent/JP2017514801A5/ja
Application granted granted Critical
Publication of JP6768515B2 publication Critical patent/JP6768515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016561311A 2014-04-07 2015-04-07 二重アシル化glp−1化合物 Active JP6768515B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163697 2014-04-07
EP14163697.7 2014-04-07
PCT/EP2015/057442 WO2015155151A1 (en) 2014-04-07 2015-04-07 Double-acylated glp-1 compounds

Publications (3)

Publication Number Publication Date
JP2017514801A JP2017514801A (ja) 2017-06-08
JP2017514801A5 true JP2017514801A5 (enExample) 2018-05-10
JP6768515B2 JP6768515B2 (ja) 2020-10-14

Family

ID=50434120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561311A Active JP6768515B2 (ja) 2014-04-07 2015-04-07 二重アシル化glp−1化合物

Country Status (6)

Country Link
US (1) US10689429B2 (enExample)
EP (1) EP3129041B1 (enExample)
JP (1) JP6768515B2 (enExample)
CN (1) CN106132985B (enExample)
ES (1) ES2741507T3 (enExample)
WO (1) WO2015155151A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
CN111050750B (zh) 2017-08-24 2024-09-24 诺和诺德股份有限公司 Glp-1组合物及其用途
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020077129A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
CN111378027B (zh) * 2018-12-29 2022-04-15 万新医药科技(苏州)有限公司 一种索玛鲁肽前体的制备方法
JP7767264B2 (ja) * 2019-09-02 2025-11-11 ノヴォ ノルディスク アー/エス Glp-1ペプチドを含む錠剤を生成するためのプロセス
JP7670698B2 (ja) 2019-11-06 2025-04-30 ノヴォ ノルディスク アー/エス 認知症におけるglp-1受容体作動薬
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー/エス 医薬製剤
US20230165939A1 (en) 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
WO2022056313A2 (en) * 2020-09-11 2022-03-17 Glympse Bio, Inc. Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
EP4222176A4 (en) 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. POLYPEPTIDE CONJUGATES AND METHODS OF USE
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
KR20240163717A (ko) 2022-03-30 2024-11-19 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如glp—1之肽治療劑的口服投與
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264243C (en) * 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
EP1239871A1 (en) 1999-11-12 2002-09-18 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US7291594B2 (en) 2002-10-11 2007-11-06 Sanwa Kagaku Kenkyusho Co., Ltd. GLP-1 derivative and preparation thereof absorbable via mucous membrane
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN101842109B (zh) 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
CN111560060A (zh) * 2009-12-16 2020-08-21 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
CN105601729A (zh) * 2010-11-09 2016-05-25 诺沃—诺迪斯克有限公司 双-酰化的glp-1衍生物
CN103298456A (zh) * 2011-01-19 2013-09-11 诺沃—诺迪斯克有限公司 Glp-1颗粒和组合物
KR101972836B1 (ko) * 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 glp-1 유도체
ES2626013T3 (es) * 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
JP6366575B2 (ja) * 2012-05-08 2018-08-01 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
AU2014210751A1 (en) * 2013-01-29 2015-08-06 Oshadi Drug Administration Ltd. Pharmaceutical compositions for oral treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2017514801A5 (enExample)
JP2014529629A5 (enExample)
JP2013543853A5 (enExample)
JP2014501712A5 (enExample)
JP2015517478A5 (enExample)
JP2015517477A5 (enExample)
JP2010538049A5 (enExample)
JP2018506507A5 (enExample)
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
TWI362392B (en) Acylated glp-1 compounds
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
JP5755398B2 (ja) 伸長されたglp−1化合物
JP2008533105A5 (enExample)
CN104519902B (zh) 双酰化glp‑1衍生物
JP2025161829A (ja) インスリン誘導体
JP2018505146A5 (enExample)
JP2024059696A (ja) 5.8~8.5のpIを有する少なくとも1つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むpH7の注射溶液
JP2012529463A5 (enExample)
JP2010529004A5 (enExample)
WO2011080102A3 (en) Glp-1 analogues and derivatives
JP2012506402A5 (enExample)
JP2023510218A (ja) 長時間作用型glp-1化合物
NZ597554A (en) Selective glucagon-like-peptide-2 (glp-2) analogues
JP2019526537A5 (enExample)
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита